45-1 Ramsey Road, Shirley, NY 11967, USA
1-631-626-9181
info@creative-biogene.com
Oncolytic Probiotics Mediated Checkpoint
Inhibition Therapies
Home Microbial Basic Research Microbial Genome Editing Service
Oncolytic Bacterial Genome Editing
Oncolytic Probiotics Mediated Checkpoint Inhibition
Therapies
Microbial Basic
Research
Microbial Genome
Editing Service
Microbial Genome
Editing Methods
Optional Genome
Editing Strains
Microbial Target
Engineering
Oncolytic Bacterial
Genome Editing
Oncolytic Probiotics
Mediated Cancer
Treatment
Oncolytic Probiotics
Mediated Checkpoint
Inhibition Therapies
Oncolytic Probiotics
Mediated CTLA-4
blockade Therapies
Checkpoint inhibitor therapy is a form of cancer immunotherapy.
The therapy targets immune checkpoints, key regulators of the
immune system that when stimulated can dampen the immune
response to an immunologic stimulus. Some cancers can protect
themselves from attack by stimulating immune checkpoint targets.
Checkpoint therapy can block inhibitory checkpoints, restoring
immune system function. Currently approved checkpoint
inhibitors target the molecules CTLA4, PD-1, and PD-L1.
Immune checkpoint inhibitors (CPI) are a promising and
increasingly popular approach in treating cancers. Recent years
have witnessed the wide application of anti-PD-1, anti-CTLA4, and
anti-PD-L1 antibodies in various types of cancer. FDA approvals
and ongoing clinical development of checkpoint inhibitors for
treatment of various cancers highlight the immense potential of
checkpoint inhibitors as anti-cancer therapeutics. Methods of
Oncolytic Probiotics Mediated
Checkpoint Inhibition Therapies
Oncolytic Probiotics
Mediated CTLA-4
blockade Therapies
Oncolytic Probiotics
Mediated PD-1 inhibitors
Therapies
Oncolytic Probiotics
Mediated PD-L1 inhibitors
Therapies
SEARCH
Please input your keywords ...
Contact Us
Creative Biogene
Promise
Our Promise to you:
Premier global
microbiological
solutions, extensive
collection of
products.
Oncolytic Probiotics
M